

Giuseppe Viale

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8082564/publications.pdf](https://exaly.com/author-pdf/8082564/publications.pdf)

Version: 2024-02-01

399
papers

64,731
citations

1524

106
h-index

906

240
g-index

536
all docs

536
docs citations

536
times ranked

58309
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 3997-4013.	15.4	3,396
2	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	1.3	2,911
3	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2784-2795.	15.4	2,732
4	A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 546-553.	30.1	1,987
5	Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. <i>Lancet, The</i> , 1997, 349, 1864-1867.	12.1	1,883
6	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1656-1664.	6.4	1,553
7	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2105-2122.	15.4	1,513
8	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	1.3	1,501
9	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	30.1	1,483
10	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , 2013, 31, 860-867.	15.4	1,390
11	Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1183-1192.	6.4	1,138
12	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 122-131.	30.1	1,077
13	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23â€“01): a phase 3 randomised controlled trial. <i>Lancet Oncology, The</i> , 2013, 14, 297-305.	10.8	1,028
14	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 241-256.	2.5	996
15	Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	30.1	894
16	Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content. <i>Cell</i> , 2010, 140, 62-73.	27.8	863
17	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018, 19, 27-39.	10.8	778
18	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	15.4	771

#	ARTICLE	IF	CITATIONS
19	Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. <i>Nature Immunology</i> , 2005, 6, 507-514.	13.9	724
20	Triple-negative breast cancer: disease entity or title of convenience?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 683-692.	27.6	720
21	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1364-1382.	2.5	692
22	Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. <i>Lancet Oncology</i> , The, 2013, 14, 1269-1277.	10.8	686
23	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2018, 19, 737-746.	10.8	681
24	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 107-118.	30.1	641
25	Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 436-446.	30.1	605
26	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-“Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 311-335.	4.4	576
27	An International Ki67 Reproducibility Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1897-1906.	6.4	513
28	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.4	501
29	HER2 testing in gastric cancer: a practical approach. <i>Modern Pathology</i> , 2012, 25, 637-650.	5.6	500
30	Sentinel Lymph Node Biopsy in Breast Cancer. <i>Annals of Surgery</i> , 2010, 251, 595-600.	4.5	480
31	Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. <i>Journal of Cell Biology</i> , 2004, 167, 215-221.	5.2	459
32	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	1.3	440
33	Calretinin: A Novel Immunocytochemical Marker for Mesothelioma. <i>American Journal of Surgical Pathology</i> , 1996, 20, 1037-1046.	3.9	436
34	Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. <i>Lancet Oncology</i> , The, 2006, 7, 983-990.	10.8	422
35	Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 3846-3852.	15.4	412
36	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962.	15.4	411

#	ARTICLE	IF	CITATIONS
37	Dissecting the Heterogeneity of Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1879-1887.	15.4	396
38	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1385-1393.	10.8	369
39	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3867-3876.	15.4	352
40	Alterations of the Notch pathway in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 22293-22298.	7.6	351
41	p63, a p53 Homologue, Is a Selective Nuclear Marker of Myoepithelial Cells of the Human Breast. <i>American Journal of Surgical Pathology</i> , 2001, 25, 1054-1060.	3.9	349
42	NUMB controls p53 tumour suppressor activity. <i>Nature</i> , 2008, 451, 76-80.	36.2	349
43	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , 2019, 20, 371-382.	10.8	345
44	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	9.8	322
45	CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 441-451.	6.4	318
46	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2014, 32, 2794-2803.	15.4	311
47	Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. <i>Journal of Clinical Oncology</i> , 2008, 26, 5569-5575.	15.4	302
48	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , 2019, 393, 1440-1452.	12.1	284
49	The fibronectin isoform containing the ed-b oncofetal domain: A marker of angiogenesis. <i>International Journal of Cancer</i> , 1994, 59, 612-618.	5.4	283
50	Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. <i>Gut</i> , 2012, 61, 1007-1015.	13.7	278
51	The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 3 positive lymph nodes in an independent validation study. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 295-302.	2.5	263
52	Genomic Characterization of Primary Invasive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1872-1881.	15.4	260
53	Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. <i>Cancer</i> , 1999, 85, 2433-2438.	4.1	246
54	HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. <i>Modern Pathology</i> , 2014, 27, 4-18.	5.6	243

#	ARTICLE	IF	CITATIONS
55	Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5693-5699.	15.4	241
56	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	5.6	241
57	Assessment of a <i>HER2</i> scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015, 28, 1481-1491.	5.6	237
58	Typical and Atypical Pulmonary Carcinoid Tumor Overdiagnosed as Small-Cell Carcinoma on Biopsy Specimens. <i>American Journal of Surgical Pathology</i> , 2005, 29, 179-187.	3.9	232
59	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. <i>Cancer Cell</i> , 2021, 39, 708-724.e11.	16.8	228
60	Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy. <i>Annals of Surgery</i> , 2005, 241, 319-325.	4.5	225
61	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 545-563.	2.5	222
62	Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 727-737.	6.4	221
63	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. <i>Modern Pathology</i> , 2015, 28, 1185-1201.	5.6	219
64	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. <i>European Journal of Cancer</i> , 2014, 50, 277-289.	2.9	218
65	Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 207-212.	6.4	217
66	Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. <i>Cancer</i> , 2001, 92, 1378-1384.	4.1	216
67	Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 349-353.	2.5	211
68	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	5.6	203
69	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	10.8	201
70	Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. <i>Cancer</i> , 2005, 103, 492-500.	4.1	198
71	Adjuvant Pertuzumab and Trastuzumab in Early <i>HER2</i> -Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	15.4	197
72	A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers. <i>Journal of the National Cancer Institute</i> , 2003, 95, 779-790.	6.4	194

#	ARTICLE	IF	CITATIONS
73	How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS ONE, 2012, 7, e37379.	2.5	182
74	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Research and Treatment, 2009, 116, 317-328.	2.5	176
75	Immunoreactivity for Thyroid Transcription Factor-1 in Stage I Non-Small Cell Carcinomas of the Lung. American Journal of Surgical Pathology, 2001, 25, 363-372.	3.9	174
76	Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Research and Treatment, 2010, 124, 607-617.	2.5	173
77	Management of triple negative breast cancer. Breast, 2010, 19, 312-321.	2.3	172
78	Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. Journal of Clinical Oncology, 2009, 27, 2962-2969.	15.4	166
79	Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis. Oncologist, 2010, 15, 1164-1168.	4.1	163
80	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials. Lancet Oncology, The, 2021, 22, 1139-1150.	10.8	163
81	Breast phyllodes tumor: A review of literature and a single center retrospective series analysis. Critical Reviews in Oncology/Hematology, 2013, 88, 427-436.	4.5	157
82	Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement. Journal of Clinical Oncology, 2005, 23, 1379-1389.	15.4	154
83	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	4.5	154
84	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of Clinical Oncology, 2016, 34, 2221-2231.	15.4	153
85	Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays. Journal of the National Cancer Institute, 2006, 98, 1571-1581.	6.4	152
86	Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology, 2015, 33, 2772-2779.	15.4	151
87	Review Article: Pulmonary Sarcomatoid Carcinomas: A Practical Overview. International Journal of Surgical Pathology, 2010, 18, 103-120.	0.8	147
88	p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer, 1997, 79, 425-432.	4.1	145
89	Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncology, The, 2008, 9, 23-28.	10.8	145
90	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncology, The, 2018, 19, 249-256.	10.8	134

#	ARTICLE	IF	CITATIONS
91	Invasive lobular breast cancer: subtypes and outcome. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 713-723.	2.5	132
92	Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome. <i>Clinical Breast Cancer</i> , 2013, 13, 31-39.	2.6	132
93	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018, 36, 1941-1948.	15.4	128
94	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.4	128
95	Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the Breast. <i>Annals of Surgery</i> , 2008, 247, 315-319.	4.5	126
96	Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. <i>Lancet Oncology</i> , The, 2021, 22, 597-608.	10.8	123
97	Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2966-2973.	15.4	122
98	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.4	120
99	A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination. <i>Journal of Cell Biology</i> , 2014, 206, 307-328.	5.2	116
100	Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. <i>Cancer Discovery</i> , 2021, 11, 2474-2487.	14.2	116
101	Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. <i>International Journal of Cancer</i> , 1996, 69, 205-211.	5.4	115
102	Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. <i>Modern Pathology</i> , 2007, 20, 843-855.	5.6	115
103	Therapeutic effect of β -blockers in triple-negative breast cancer postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 567-575.	2.5	115
104	Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. <i>Breast</i> , 2017, 31, 51-56.	2.3	114
105	Paget's disease of the breast: the experience of the European institute of oncology and review of the literature. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 513-521.	2.5	113
106	Evolution of low HER2 expression between early and advanced-stage breast cancer. <i>European Journal of Cancer</i> , 2022, 163, 35-43.	2.9	111
107	Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. <i>EMBO Journal</i> , 2004, 23, 1144-1154.	8.2	110
108	Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant Antibody. <i>American Journal of Pathology</i> , 1999, 154, 1345-1352.	4.1	108

#	ARTICLE	IF	CITATIONS
109	Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 413-422.	2.9	107
110	Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. <i>European Journal of Surgical Oncology</i> , 2021, 47, 804-812.	1.0	105
111	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 323-331.	2.5	101
112	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020, 38, 1293-1303.	15.4	100
113	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	5.4	100
114	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	14.2	100
115	Comparative Evaluation of an Extensive Histopathologic Examination and a Real-Time Reverse-Transcription-Polymerase Chain Reaction Assay for Mammaglobin and Cytokeratin 19 on Axillary Sentinel Lymph Nodes of Breast Carcinoma Patients. <i>Annals of Surgery</i> , 2008, 247, 136-142.	4.5	99
116	Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1404-1410.	15.4	98
117	Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. <i>Cancer</i> , 1992, 70, 2268-2277.	4.1	95
118	Conservative surgery in patients with multifocal/multicentric breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 577-583.	2.5	95
119	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014, 23, 69-75.	2.3	93
120	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	10.8	93
121	PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus Nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1733-1743.	6.4	91
122	Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. <i>Modern Pathology</i> , 2005, 18, 1277-1282.	5.6	90
123	Pleomorphic Carcinomas of the Lung Show a Selective Distribution of Gene Products Involved in Cell Differentiation, Cell Cycle Control, Tumor Growth, and Tumor Cell Motility. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1203-1215.	3.9	89
124	Nodal Stage Classification for Breast Carcinoma: Improving Interobserver Reproducibility Through Standardized Histologic Criteria and Image-Based Training. <i>Journal of Clinical Oncology</i> , 2008, 26, 258-263.	15.4	89
125	An Atlas of Altered Expression of Deubiquitinating Enzymes in Human Cancer. <i>PLoS ONE</i> , 2011, 6, e15891.	2.5	89
126	The outcome from acute subdural and epidural intracranial haematomas in very elderly patients. <i>British Journal of Neurosurgery</i> , 1992, 6, 227-231.	0.9	88

#	ARTICLE	IF	CITATIONS
127	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2002, 118, 817-820.	2.7	88
128	Ultrasound-guided vacuum-assisted core breast biopsy: experience with 406 cases. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 103-110.	2.5	87
129	Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 359-369.	2.5	86
130	Ectopic Breast Tissue as a Possible Cause of False-Positive Axillary Sentinel Lymph Node Biopsies. <i>American Journal of Surgical Pathology</i> , 2003, 27, 513-518.	3.9	84
131	Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1â€“98. <i>Breast Cancer Research</i> , 2019, 21, 30.	5.1	83
132	Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 weekly paclitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 667-672.	2.4	82
133	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.	6.4	81
134	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 644737.	2.9	81
135	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. <i>Histopathology</i> , 2019, 75, 225-235.	3.1	80
136	Sentinel Lymph Node Metastasis in Microinvasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2003, 10, 1160-1165.	2.0	79
137	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERÎ± metastatic breast cancer. <i>Nature Genetics</i> , 2017, 49, 444-450.	20.4	79
138	RAB2A controls MT1â€“MMP endocytic and Eâ€“cadherin polarized Golgi trafficking to promote invasive breast cancer programs. <i>EMBO Reports</i> , 2016, 17, 1061-1080.	5.1	78
139	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. <i>JAMA Oncology</i> , 2016, 2, 1040.	7.3	76
140	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.	3.6	76
141	Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. <i>International Journal of Cancer</i> , 2001, 95, 307-312.	5.4	73
142	CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 782-786.	2.9	73
143	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2Î± Scaffolding Function. <i>Cancer Cell</i> , 2017, 32, 444-459.e7.	16.8	73
144	Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2020, 84, 101963.	8.0	73

#	ARTICLE	IF	CITATIONS
145	The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. <i>EMBO Molecular Medicine</i> , 2011, 3, 480-494.	7.3	72
146	Pancreatic (Acinar) Metaplasia of the Gastric Mucosa. <i>American Journal of Surgical Pathology</i> , 1993, 17, 1134-1143.	3.9	70
147	Extensive Frozen Section Examination of Axillary Sentinel Nodes to Determine Selective Axillary Dissection. <i>World Journal of Surgery</i> , 2001, 25, 806-808.	1.4	69
148	Second Biopsy of Axillary Sentinel Lymph Node for Reappearing Breast Cancer After Previous Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2005, 12, 895-899.	2.0	69
149	Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 689-699.	2.5	66
150	The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study. <i>Acta Oncologica</i> , 2012, 51, 653-661.	1.9	66
151	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408.	15.4	66
152	Pulmonary Epithelial-Myoepithelial Tumor of Unproven Malignant Potential: Report of a Case and Review of the Literature. <i>Modern Pathology</i> , 2001, 14, 521-526.	5.6	65
153	Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. <i>Cancer</i> , 2004, 101, 905-912.	4.1	65
154	Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 819-825.	2.5	65
155	Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration. <i>American Journal of Clinical Pathology</i> , 2015, 144, 629-634.	0.7	65
156	Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. <i>BMJ</i> , The, 2021, 375, e066381.	7.8	65
157	Vasoactive intestinal polypeptide-, somatostatin-, and calcitonin-producing adrenal pheochromocytoma associated with the watery diarrhea (WDHH) syndrome. First case report with immunohistochemical findings. <i>Cancer</i> , 1985, 55, 1099-1106.	4.1	64
158	Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 21535-21540.	7.6	63
159	Sentinel node biopsy in male breast cancer. <i>Nuclear Medicine Communications</i> , 2004, 25, 139-143.	1.1	62
160	Rethinking TNM: Breast cancer TNM classification for treatment decision-making and research. <i>Breast</i> , 2006, 15, 3-8.	2.3	61
161	Immunohistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid) Tj ETQq1 1 0.784314 rgBT /Ove Parallels the Corresponding Profiling and Eventual Diagnoses on Surgical Specimens. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1039-1049.	1.2	60
162	Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity. <i>Clinical Breast Cancer</i> , 2012, 12, 207-214.	2.6	60

#	ARTICLE	IF	CITATIONS
163	Accuracy of computed tomography and magnetic resonance imaging in the detection of lymph node involvement in cervix carcinoma. <i>European Radiology</i> , 2005, 15, 2469-2474.	4.6	59
164	Be precise! The need to consider the mechanisms for <i>CEP17</i> copy number changes in breast cancer. <i>Journal of Pathology</i> , 2009, 219, 1-2.	4.5	59
165	Hormone receptor expression and activity of trastuzumab with chemotherapy in HER2 positive advanced breast cancer patients. <i>Cancer</i> , 2012, 118, 17-26.	4.1	59
166	Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 485-492.	2.5	59
167	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014, 21, 545-554.	3.0	59
168	The clinical relevance of micropapillary carcinoma of the breast: a case-control study. <i>Histopathology</i> , 2013, 63, 217-224.	3.1	56
169	Immunohistochemically Defined Subtypes and Outcome of Apocrine Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 95-102.	2.6	56
170	Angiopoietin-like 7, a novel pro-angiogenic factor over-expressed in cancer. <i>Angiogenesis</i> , 2014, 17, 881-896.	7.2	56
171	Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL). <i>Journal of Pathology</i> , 1997, 181, 323-329.	4.5	55
172	K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. <i>Modern Pathology</i> , 2004, 17, 538-546.	5.6	55
173	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	7.2	55
174	Lapatinib Activity in Premalignant Lesions and HER-2 Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial. <i>Cancer Prevention Research</i> , 2011, 4, 1181-1189.	1.6	53
175	Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression. <i>Clinical Breast Cancer</i> , 2014, 14, 258-264.	2.6	52
176	Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. <i>Journal of Controlled Release</i> , 2018, 280, 76-86.	10.2	52
177	Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. <i>Annals of Surgical Oncology</i> , 2002, 9, 266-271.	2.0	51
178	CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 449-455.	2.9	51
179	Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 867-875.	2.5	51
180	The Problem of the Accuracy of Intraoperative Examination of Axillary Sentinel Nodes in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 817-820.	2.0	50

#	ARTICLE	IF	CITATIONS
181	Impact of updated HER2 testing guidelines in breast cancer – re-evaluation of HERA trial fluorescence in situ hybridization data. <i>Modern Pathology</i> , 2015, 28, 1528-1534.	5.6	49
182	Primary and secondary angiosarcomas of the breast: a single institution experience. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1081-1088.	2.5	48
183	Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 81-85.	2.5	47
184	Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. <i>Journal of Allergy and Clinical Immunology</i> , 1983, 72, 294-298.	2.9	46
185	CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. <i>Modern Pathology</i> , 2004, 17, 711-721.	5.6	46
186	Rethinking TNM: A Breast Cancer Classification to Guide to Treatment and Facilitate Research. <i>Breast Journal</i> , 2009, 15, 291-295.	1.1	46
187	A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). <i>Breast Cancer Research and Treatment</i> , 2021, 190, 265-275.	2.5	45
188	LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion. <i>Nature Genetics</i> , 2022, 54, 180-193.	20.4	45
189	p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations. <i>Journal of Pathology</i> , 1999, 187, 302-307.	4.5	43
190	Clear Cell Odontogenic Carcinoma. <i>American Journal of Clinical Pathology</i> , 2001, 116, 107-114.	0.7	43
191	Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. <i>Journal of Clinical Oncology</i> , 2020, 38, 2883-2891.	15.4	43
192	CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 270-274.	2.9	42
193	Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. <i>Journal of Pathology</i> , 1998, 185, 167-174.	4.5	41
194	Systemic therapy as a first choice treatment for idiopathic granulomatous mastitis. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 689-691.	1.5	41
195	Metaplastic breast cancer: Prognostic and therapeutic considerations. <i>Journal of Surgical Oncology</i> , 2021, 123, 61-70.	1.7	41
196	p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity. <i>Laboratory Investigation</i> , 2002, 82, 1327-1334.	3.9	40
197	The evolution of the conservative approach to breast cancer. <i>Breast</i> , 2007, 16, 120-129.	2.3	39
198	Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. <i>Breast</i> , 2011, 20, 319-323.	2.3	39

#	ARTICLE	IF	CITATIONS
199	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1954-1960.	15.4	39
200	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. <i>EBioMedicine</i> , 2019, 42, 352-362.	6.0	39
201	Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 157-165.	2.5	38
202	An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 62-72.	7.2	38
203	Involvement of BCL-2 Oncoprotein in the Development of Enterochromaffin-like Cell Gastric Carcinoids. <i>American Journal of Surgical Pathology</i> , 1996, 20, 433-441.	3.9	38
204	Positive Identification in Situ of mRNA Expression of IL-6, and IL-12, and the Chemotactic Cytokine RANTES in Patients with Chronic Sinusitis and Polypoid Disease Clinical Relevance and Relation to Allergy. <i>Acta Oto-Laryngologica</i> , 1996, 116, 604-610.	0.9	37
205	Gene Status in <i>HER2</i> Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based Method. <i>Oncologist</i> , 2014, 19, 1118-1126.	4.1	37
206	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 275-286.	2.5	37
207	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1335.	7.3	37
208	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	2.5	37
209	A Primary Pure Yolk Sac Tumor of the Lung Exhibiting CDX-2 Immunoreactivity and Increased Serum Levels of Alkaline Phosphatase Intestinal Isoenzyme. <i>International Journal of Surgical Pathology</i> , 2006, 14, 247-251.	0.8	35
210	Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 131-137.	2.5	35
211	HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 239-245.	1.2	35
212	Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 259-265.	2.6	34
213	Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. <i>Breast</i> , 2016, 30, 151-155.	2.3	34
214	Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers. <i>EMBO Molecular Medicine</i> , 2017, 9, 655-671.	7.3	34
215	Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients. <i>Journal of Surgical Oncology</i> , 2004, 85, 123-128.	1.7	33
216	Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. <i>International Journal of Cancer</i> , 2005, 113, 101-108.	5.4	33

#	ARTICLE	IF	CITATIONS
217	Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1332-1334.	6.4	33
218	Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. <i>Breast Cancer Research</i> , 2020, 22, 107.	5.1	33
219	Topoisomerase III \pm gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. <i>Breast</i> , 2008, 17, 506-511.	2.3	32
220	Pirin Inhibits Cellular Senescence in Melanocytic Cells. <i>American Journal of Pathology</i> , 2011, 178, 2397-2406.	4.1	32
221	Pathological features and survival outcomes of very young patients with early breast cancer: How much is "every young"? <i>Breast</i> , 2013, 22, 1046-1051.	2.3	32
222	Outcome of Male Breast Cancer: A Matched Single-Institution Series. <i>Clinical Breast Cancer</i> , 2014, 14, 371-377.	2.6	32
223	Reply to E.A. Rakha et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1302-1304.	15.4	32
224	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper $\text{\textcircled{R}}$. <i>Breast Cancer Research</i> , 2017, 19, 55.	5.1	32
225	Down-Regulation of β 1C Integrin in Breast Carcinomas Correlates with High Proliferative Fraction, High Histological Grade, and Larger Size. <i>American Journal of Pathology</i> , 2000, 156, 169-174.	4.1	31
226	Progesterone receptor immunoreactivity in minute meningothelioid nodules of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 543-546.	2.9	31
227	Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer Is Rare. <i>Journal of Clinical Oncology</i> , 2004, 22, 4966-4970.	15.4	31
228	Pathologic examination of the axillary sentinel lymph nodes in patients with early-stage breast carcinoma: current and resolving controversies on the basis of the European Institute of Oncology experience. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 241-247.	2.9	31
229	Follicular dendritic cell sarcoma of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 194-199.	2.9	29
230	Basaloid cell carcinoma of the prostate. Case report and review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 787-791.	2.9	29
231	OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. <i>Liver International</i> , 2019, 39, 158-167.	4.0	29
232	Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: Identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. <i>International Journal of Cancer</i> , 2003, 106, 288-291.	5.4	28
233	Conservative Treatment of Breast Cancer: Its Evolution. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 195-198.	2.5	28
234	Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 431-441.	2.5	28

#	ARTICLE	IF	CITATIONS
235	Outcomes of Patients With Breast Cancer Who Present With Ipsilateral Supraclavicular or Internal Mammary Lymph Node Metastases. <i>Clinical Breast Cancer</i> , 2014, 14, 53-60.	2.6	28
236	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. <i>Breast</i> , 2015, 24, 290-293.	2.3	28
237	Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 451-458.	2.5	28
238	Patterns of integrin common chain $\beta 1$ and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size. <i>Journal of Pathology</i> , 1993, 171, 5-11.	4.5	27
239	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. <i>International Journal of Cancer</i> , 2001, 92, 666-670.	5.4	27
240	Branchiogenic carcinoma – conceptual or true clinico-pathological entity?. <i>Cancer Treatment Reviews</i> , 2005, 31, 106-114.	8.0	27
241	Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment. <i>Acta Oncologica</i> , 2015, 54, 1040-1048.	1.9	27
242	FAT1: a potential target for monoclonal antibody therapy in colon cancer. <i>British Journal of Cancer</i> , 2016, 115, 40-51.	6.6	27
243	Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 442-448.	2.9	26
244	Pathological definition of triple negative breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 5-10.	2.9	26
245	CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 373-384.	2.5	26
246	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103643.	4.5	26
247	Long-term follow-up of the surgical treatment of intracranial coenurosis. <i>British Journal of Neurosurgery</i> , 1990, 4, 39-43.	0.9	25
248	Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. <i>Clinical Breast Cancer</i> , 2008, 8, 436-442.	2.6	25
249	Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 2879-2884.	2.0	25
250	Biopsy of liver metastasis for women with breast cancer: Impact on survival. <i>Breast</i> , 2012, 21, 284-288.	2.3	25
251	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. <i>Breast</i> , 2014, 23, 44-49.	2.3	25
252	Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 327-335.	2.5	25

#	ARTICLE	IF	CITATIONS
253	Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial. <i>Cancer Prevention Research</i> , 2015, 8, 888-894.	1.6	25
254	Lobular Metastatic Breast Cancer Patients With Gastrointestinal Involvement: Features and Outcomes. <i>Clinical Breast Cancer</i> , 2018, 18, e401-e405.	2.6	25
255	Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. <i>Oncologist</i> , 2019, 24, 165-171.	4.1	25
256	Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020, 49, 202-209.	2.3	25
257	Definition of High-Risk Early Hormone-Positive HER2 ⁻ Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.8	25
258	Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. <i>Cancer</i> , 1994, 74, 134-141.	4.1	24
259	Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. <i>Modern Pathology</i> , 2003, 16, 886-892.	5.6	22
260	Nonpalpable Breast Carcinomas: Long-Term Evaluation of 1,258 Cases. <i>Oncologist</i> , 2010, 15, 1248-1252.	4.1	22
261	ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer. <i>Oncotarget</i> , 2016, 7, 63596-63610.	2.1	22
262	Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. <i>Breast Cancer Research</i> , 2016, 18, 110.	5.1	22
263	A Trust-Based Pact in Research Biobanks. From Theory to Practice. <i>Bioethics</i> , 2016, 30, 260-271.	1.6	22
264	Lack of Diagnostic Utility of Vimentin Immunostaining. <i>American Journal of Surgical Pathology</i> , 1989, 13, 1034-1040.	3.9	21
265	Immunoreactivity for p27KIP1 and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2001, 94, 599-604.	5.4	21
266	Salivary Gland-Type Tumors With Myoepithelial Differentiation Arising in Pulmonary Hamartoma. <i>American Journal of Surgical Pathology</i> , 2006, 30, 375-387.	3.9	21
267	Ductal Intraepithelial Neoplasia: Postsurgical Outcome for 1,267 Women Cared for in One Single Institution over 10 Years. <i>Oncologist</i> , 2009, 14, 201-212.	4.1	21
268	Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 483-488.	2.6	21
269	Pathological work up of the primary tumor: Getting the proper information out of it. <i>Breast</i> , 2011, 20, S82-S86.	2.3	21
270	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , 2016, 2, 217.	7.3	21

#	ARTICLE	IF	CITATIONS
271	The Dilemma of HER2 Double-equivocal Breast Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1190-1200.	3.9	21
272	Endomyocardial biopsy guided by intracardiac echocardiography as a key step in intracardiac mass diagnosis. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 15.	1.7	21
273	Identification of a novel KRIT1 mutation in an Italian family with cerebral cavernous malformation by the protein truncation test. <i>Journal of the Neurological Sciences</i> , 2003, 212, 75-78.	0.6	20
274	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. <i>Modern Pathology</i> , 2004, 17, 1513-1520.	5.6	20
275	Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 965-971.	2.4	20
276	Insulin-like growth factor-I expression in normal and diseased endometrium. <i>International Journal of Cancer</i> , 1999, 80, 188-193.	5.4	19
277	Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status. <i>Breast</i> , 2013, 22, 200-202.	2.3	19
278	Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 463-469.	2.5	19
279	The Lymph Node and the Metastasis. <i>New England Journal of Medicine</i> , 2018, 378, 2045-2046.	30.1	19
280	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 386-395.	15.4	19
281	Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. <i>British Journal of Haematology</i> , 2003, 120, 695-698.	2.7	18
282	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. <i>Anti-Cancer Drugs</i> , 2009, 20, 197-203.	1.4	18
283	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	7.2	18
284	A role for the immune system in advanced laryngeal cancer. <i>Scientific Reports</i> , 2020, 10, 18327.	3.4	18
285	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021, 145, 197-209.	2.9	18
286	Pathology after neoadjuvant treatment – How to assess residual disease. <i>Breast</i> , 2022, 62, S25-S28.	2.3	18
287	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	5.4	18
288	Pulsed Dose-Rate Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas of the Extremities and Skeletal Muscles of the Trunk. <i>Annals of Surgical Oncology</i> , 2005, 12, 935-942.	2.0	17

#	ARTICLE	IF	CITATIONS
289	Histopathology of primary breast cancer 2005. <i>Breast</i> , 2005, 14, 487-492.	2.3	17
290	Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 185-190.	2.5	17
291	Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 7-15.	2.9	17
292	Ultrasound-guided vacuum assisted breast biopsy in the assessment of C3 breast lesions by ultrasound-guided fine needle aspiration cytology: Results and costs in comparison with surgery. <i>Breast</i> , 2009, 18, 73-77.	2.3	17
293	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology</i> , The, 2011, 12, 1162-1168.	10.8	17
294	Influence of Margin Status on Outcomes in Lobular Carcinoma. <i>Annals of Surgery</i> , 2011, 253, 580-584.	4.5	17
295	Characterization and clinical impact of residual disease after neoadjuvant chemotherapy. <i>Breast</i> , 2013, 22, S88-S91.	2.3	17
296	Origin and function of tomato bushy stunt virus-induced inclusion bodies. <i>Journal of Structural Biology</i> , 1986, 97, 31-38.	0.8	16
297	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. <i>International Journal of Cancer</i> , 2004, 112, 71-77.	5.4	16
298	ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 543-555.	2.5	16
299	Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2024, 484, 3-14.	2.9	16
300	Posterior polymorphous dystrophy of the cornea. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 1985, 223, 265-271.	1.9	15
301	Cellular heterogeneity of granular cell tumours: a clue to their nature?. <i>Journal of Oral Pathology and Medicine</i> , 2000, 29, 284-290.	2.7	15
302	A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear β -catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 447, 969-977.	2.9	15
303	Core needle biopsy as a front line diagnostic approach for lymphoma patients. <i>Hematological Oncology</i> , 2015, 33, 247-249.	1.8	15
304	Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 173-181.	0.8	15
305	Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer. <i>Breast</i> , 2007, 16, 73-80.	2.3	14
306	The sentinel node biopsy under local anesthesia in breast cancer: Advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases. <i>Breast</i> , 2007, 16, 527-532.	2.3	14

#	ARTICLE	IF	CITATIONS
307	Axillary Lymph Node Involvement in Women With Breast Cancer: Does It Depend on Age?. <i>Clinical Breast Cancer</i> , 2010, 10, 318-321.	2.6	14
308	Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. <i>Breast</i> , 2015, 24, 263-271.	2.3	14
309	The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. <i>Journal of Clinical Pathology</i> , 2018, 71, 767-773.	2.2	14
310	Advances and controversies in management of breast ductal carcinoma in situ (DCIS). <i>European Journal of Surgical Oncology</i> , 2022, 48, 736-741.	1.0	14
311	Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 15-29.	5.5	13
312	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. <i>Genome Medicine</i> , 2020, 12, 94.	8.5	13
313	Post-radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with long-term follow-up and literature review. <i>Histopathology</i> , 2020, 77, 293-302.	3.1	13
314	Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 604-612.	2.9	12
315	The Rete Mirabile of the Cranial Base: A Millenary Legend. <i>Neurosurgery</i> , 2006, 58, 1198-1208.	1.3	12
316	Immunoreactivity for Sex Steroid Hormone Receptors in Pulmonary Hamartomas. <i>American Journal of Surgical Pathology</i> , 2006, 30, 819-827.	3.9	12
317	The TNM classification of breast cancer: need for change. <i>Updates in Surgery</i> , 2010, 62, 75-81.	2.1	12
318	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1186-1197.	15.4	12
319	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. <i>Breast</i> , 2021, 59, 94-101.	2.3	12
320	Cytological features of calcifying epithelial odontogenic tumor (Pindborg tumor) with abundant cementum-like material. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 442, 107-110.	2.9	11
321	A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 1201-1209.	1.4	11
322	Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. <i>Breast</i> , 2007, 16, 262-270.	2.3	11
323	The AURORA pilot study for molecular screening of patients with advanced breast cancer—a study of the breast international group. <i>Npj Breast Cancer</i> , 2017, 3, 23.	5.4	11
324	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	3.2	11

#	ARTICLE	IF	CITATIONS
325	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII and IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 557-568.	2.5	11
326	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. <i>Breast Cancer Research</i> , 2019, 21, 153.	5.1	11
327	Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy. <i>Breast</i> , 2020, 53, 138-142.	2.3	11
328	Integrating molecular profiling, histological type and other variables: Defining the fingerprint of responsiveness to treatment. <i>Breast</i> , 2009, 18, S32-S36.	2.3	10
329	Prevalence and Clinicopathologic Correlates of O6-Methylguanine-DNA Methyltransferase Methylation Status in Patients With Triple-Negative Breast Cancer Treated Preoperatively by Alkylating Drugs. <i>Clinical Breast Cancer</i> , 2014, 14, 285-290.	2.6	10
330	Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 573-582.	2.5	10
331	Radioablation + ¹⁷⁷ Lu hormone therapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). <i>BMC Cancer</i> , 2019, 19, 903.	2.6	10
332	Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. <i>Radiotherapy and Oncology</i> , 2019, 133, 68-76.	0.6	10
333	Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 497-503.	2.9	9
334	Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1203-1212.	1.8	9
335	Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence. <i>Breast</i> , 2014, 23, 829-835.	2.3	9
336	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018, 52, 424-432.	3.2	9
337	TCTN2: a novel tumor marker with oncogenic properties. <i>Oncotarget</i> , 2017, 8, 95256-95269.	2.1	9
338	Adult Nephroblastoma Induced Erythrocytosis. <i>Scandinavian Journal of Urology and Nephrology</i> , 1990, 24, 159-161.	1.3	8
339	Histopathology of primary breast cancer 2003. <i>Breast</i> , 2003, 12, 391-396.	2.3	8
340	Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. <i>Breast</i> , 2008, 17, 654-660.	2.3	8
341	Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. <i>Oncologist</i> , 2010, 15, 665-672.	4.1	8
342	Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluorouracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. <i>Breast</i> , 2011, 20, 34-38.	2.3	8

#	ARTICLE	IF	CITATIONS
343	Intravascular Papillary Endothelial Hyperplasia of the Renal Vein. <i>International Journal of Surgical Pathology</i> , 2011, 19, 518-520.	0.8	8
344	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 67.	5.4	8
345	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. <i>Frontiers in Oncology</i> , 2021, 11, 723693.	2.9	8
346	Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (<i>ALK</i>) alterations in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 37160-37176.	2.1	8
347	Sex as a predictor of response to cancer immunotherapy – Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e380-e381.	10.8	7
348	Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 112.	2.5	7
349	Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. <i>Tumori</i> , 2022, 108, 196-203.	1.1	7
350	Adenomyoepithelioma of the Breast, Presenting as a Cancer. <i>Tumori</i> , 2004, 90, 337-339.	1.1	6
351	Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies. <i>Current Opinion in Oncology</i> , 2010, 22, 541-546.	2.5	6
352	Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer. <i>Breast</i> , 2010, 19, 128-132.	2.3	6
353	Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 303-310.	2.5	6
354	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	7.2	6
355	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. <i>Cancers</i> , 2021, 13, 3278.	3.8	6
356	Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer – A Europe-Wide External Quality Assessment. <i>Cancers</i> , 2021, 13, 4718.	3.8	6
357	Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. <i>Current Oncology</i> , 2021, 28, 5167-5178.	2.3	6
358	Ovarian Serous Papillary Carcinoma, Metastatic to Intramammary Lymph-node Mimic a Primary Breast Carcinoma on RX Mammography. <i>Breast Journal</i> , 2012, 18, 484-485.	1.1	5
359	A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. <i>Breast</i> , 2012, 21, 621-628.	2.3	5
360	A case of NUT midline carcinoma with no HPV infection, slight EWSR1 rearrangement and strong expression of EGFR. <i>Tumori</i> , 2013, 99, e152-e155.	1.1	5

#	ARTICLE	IF	CITATIONS
361	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 351-360.	2.5	5
362	Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease. <i>Breast</i> , 2019, 48, S49-S52.	2.3	5
363	Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. <i>Lancet Oncol</i> 2018;19:737-46. <i>European Urology</i> , 2019, 75, e34-e35.	5.0	5
364	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 38-47.	6.6	5
365	Complex Differential Diagnosis between Primary Breast Cancer and Breast Metastasis from EGFR-Mutated Lung Adenocarcinoma: Case Report and Literature Review. <i>Current Oncology</i> , 2021, 28, 3384-3392.	2.3	5
366	The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2022, 33, e628-e634.	1.4	5
367	Prediction of cancer outcome with microarrays. <i>Lancet, The</i> , 2005, 365, 1685-1686.	12.1	4
368	Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1735-1736.	6.4	4
369	A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response. <i>Breast</i> , 2015, 24, S23-S25.	2.3	4
370	Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2499-2505.	1.0	4
371	The Problem of the Accuracy of Intraoperative Examination of Axillary Sentinel Nodes in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2001, 8, 817-820.	2.0	4
372	Reply to V. Arena et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e61-e61.	15.4	3
373	Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. <i>Modern Pathology</i> , 2020, 33, 1065-1077.	5.6	3
374	Pathologic and Biological Prognostic Factors of Breast Cancers in Short- and Long-Term Hormone Replacement Therapy Users. <i>Annals of Surgical Oncology</i> , 2002, 9, 266-271.	2.0	3
375	Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials. <i>Breast</i> , 2023, 69, 258-264.	2.3	3
376	Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00. <i>Clinical Cancer Research</i> , 2023, 29, 4908-4919.	7.2	3
377	Sentinel-Node Biopsy to Avoid Axillary Dissection in Breast Cancer with Clinically Negative Lymph-Nodes. <i>Breast Journal</i> , 1998, 4, 63-63.	1.1	2
378	Reply to D. Crivellari et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e258-e259.	15.4	2

#	ARTICLE	IF	CITATIONS
379	Identification of New Hematopoietic Cell Subsets with a Polyclonal Antibody Library Specific for Neglected Proteins. <i>PLoS ONE</i> , 2012, 7, e34395.	2.5	2
380	Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. <i>Clinical Breast Cancer</i> , 2015, 15, e257-e262.	2.6	2
381	Correlation of size and focality with prognosis in small breast carcinoma: a single institution case series. <i>Breast</i> , 2020, 54, 164-169.	2.3	2
382	DNA Derived from Archival Tumor Specimens can be Used for Germline Pharmacogenetic Analyses. <i>Pharmacogenomics</i> , 2020, 21, 899-902.	1.4	2
383	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. <i>European Journal of Cancer</i> , 2022, 164, 52-61.	2.9	2
384	Ultrastructural Formation of Langerhans Cell Granules in a Case of Histiocytosis X. <i>Ultrastructural Pathology</i> , 1989, 13, 89-91.	0.9	1
385	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , 2008, 32, 1628-1632.	1.1	1
386	Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience. <i>Clinical Breast Cancer</i> , 2015, 15, 440-447.	2.6	1
387	Controversies in treatment selection for patients with equivocal ER and HER2 results. <i>Breast</i> , 2017, 34, S61-S63.	2.3	1
388	From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. <i>Breast</i> , 2017, 31, 241-243.	2.3	1
389	Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz051.	2.8	1
390	Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. <i>Clinical Cancer Research</i> , 2024, 30, 1093-1103.	7.2	1
391	Integrin common chain β 1 immunoreactivity in hepatocellular carcinoma. <i>Journal of Pathology</i> , 1994, 172, 363-364.	4.5	0
392	An Intriguing Fragment of Pre-Hippocratic Medicine in Aeschylus. <i>Neurosurgery</i> , 2004, 55, 761-766.	1.3	0
393	Further Axillary Metastases Associated With Isolated Tumor Cells in Sentinel Lymph Nodes of Breast Cancer Patients. <i>Annals of Surgery</i> , 2006, 243, 287.	4.5	0
394	Reply to letter by leni et al.. <i>European Journal of Cancer</i> , 2014, 50, 1038-1039.	2.9	0
395	CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER (HER2+ BC): DESTINY-BREAST12. <i>Neuro-Oncology Advances</i> , 2021, 3, iv4-iv4.	0.7	0
396	Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 137-145.	2.5	0

#	ARTICLE	IF	CITATIONS
397	Abstract OT2-26-01: Open-label, multinational, multicenter, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): DESTINY-Breast12. Cancer Research, 2022, 82, OT2-26-01-OT2-26-01.	0.9	0
398	Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update. Journal of Clinical Oncology, 0, , .	15.4	0
399	The Immune-Related 27-Gene Signature Determined by RNA Sequencing Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research, 0, , OF1-OF10.	7.2	0